Acrivastine
(British Approved Name, US Adopted Name, rINN)
Drug Nomenclature
Adverse Effects and Precautions
As for the non-sedating antihistamines in general. Acrivastine should be given with care in renal impairment UK licensed product information recommends that it should not be given to patients with significant renal impairment, while product information in other countries, such as Switzerland for example, contra-indicates its use in those with a creatinine clearance of less than 50 mL/minute. Acrivastine should not be used in patients hypersensitive to triprolidine.
Sedation. For a discussion of the sedative effects of antihistamines.
Interactions
As for the non-sedating antihistamines in general.
Pharmacokinetics
Acrivastine is well absorbed from the gastrointestinal tract peak plasma concentrations are achieved in about 1.5 hours. The plasma half-life of acrivastine is about 1.5 hours and the drug does not appear to cross the blood-brain barrier to a significant extent. Acrivastine along with an active metabolite is excreted principally in the urine.
Uses and Administration
Acrivastine is anon-sedating antihistamine structurally related to triprolidine. It does not have any significant sedative or antimuscarinic actions. It is used for the symptomatic relief of allergic conditions such as rhinitis and various types of urticaria when it is given in oral doses of 8 mg three times daily. It is also used with a decongestant such as pseudoephedrine hydrochloride.
Preparations
Proprietary Preparations
Austria: Semprex
Czech Republic: Semprex
Denmark: Benadryl
Finland: Benadryl Semprex
Hong Kong: Semprex
Italy: Semprex
Malaysia: Semprex
The Netherlands: Semprex
Philippines: Semprex
Russia: Semprex
South Africa: Semprex
Singapore: Semprex
Sweden: Semprex
Switzerland: Semprex
Thailand: Semprex
Turkey: Semprex
United Kingdom: Benadryl Allergy Relief
Multi-ingredient
Austria: Duact
Denmark: Duact
Finland: Duact
Turkey: Duact
UK: Benadryl Plus
USA: Semprex-D
This post has been viewed 8715 times.